

AfroCentric Investment Corporation Limited
(Incorporated in the Republic of South Africa)
(Registration number 1988/000570/06)
JSE Code: ACT ISIN: ZAE000078416
("AfroCentric" or "the Company")



Summarised results for the six months ended 31 December 2024

Introduction to the AfroCentric Group

AfroCentric is a BEE Level 1, JSE Limited listed investment holding company, which owns and operates a diverse range of healthcare-related enterprises that provide specialised medical scheme administration services and deliver a range of healthcare products and services to the public and private healthcare sectors. The principal objective of the Group is to ensure the delivery of efficient health management services and the distribution of quality products - all at a manageable and affordable cost for the benefit of our stakeholders. AfroCentric has successfully broadened its interests in the industry by continuing to pursue new opportunities to expand and rationalise its presence across the healthcare sector.

On 1 November 2024, the Company announced on SENS that it has changed its financial year-end from 30 June to 31 December, with effect from 31 December 2024. The comparative figures presented are in respect of the year ended 30 June 2024 and as such may not be comparable to the current reporting period.

The Board presents a summary of the Company's results for the six months ended 31 December 2024.

Salient Features

	% change	Six months ended 31 December 2024	Year ended 30 June 2024
Total revenue from contracts with customers (R' million)	(51.8)	4 240.9	8 794.7
(Loss)/Profit before tax (R' million)	(127.0)	(55.79)	206.98
(Loss)/Profit for the period (R' million)	(260.4)	(119.15)	74.26
Basic (loss)/earnings (R' million)	(327.3)	(125.87)	55.38
Headline earnings (R' million)	(90.5)	31.93	334.81
Basic (loss)/earnings (cents per share)	(324.3)	(14.96)	6.67
Headline earnings (cents per share)	(90.6)	3.80	40.32
Weighted average number of ordinary shares		841.09 million	830.33 million
Dividend declared (cents per share)		6	11

Dividends

The Board is pleased to announce that a final gross dividend of 6 cents per ordinary share, has been declared for the period ended 31 December 2024. Dividends are subject to Dividends Withholding Tax. The payment date for the dividend is Monday, 12 May 2025.

- Dividends have been declared out of profits available for distribution.
- South African Dividends Withholding Tax rate is 20%.
- The gross dividend amount is 6.00000 cents per ordinary share.
- Net cash dividend amount is therefore 4.80000 cents per ordinary share.
- The Company has 841 088 241 ordinary shares in issue as at the declaration date.
- The Company's income tax reference number is 9600148713

The salient dates relating to the dividend are as follows:

Last day to trade cum dividend	Tuesday, 6 May 2025
Shares commence trading ex-dividend	Wednesday, 7 May 2025
Dividend record date	Friday, 09 May 2025
Dividend payment date	Monday, 12 May 2025

Share certificates for ordinary shares may not be dematerialised or materialised between Wednesday, 7 May 2025 and Friday, 9 May 2025, both days inclusive.

Full Announcement

This short-form announcement is the responsibility of the Directors of the Company and is a summary of the information contained in the summarised results for the six months ended 31 December 2024 which were released on 3 March 2025 and can be found on the Company's website (<http://www.afrocentric.za.com/inv-reporting.php>).

The financial statements for the six months ended 31 December 2024 were released on SENS on 3 March 2025 and are available for viewing on the following websites:

Company's website: <http://www.afrocentric.za.com/inv-reporting.php>.

JSE website: <https://senspdf.jse.co.za/documents/2025/JSE/ISSE/ACT/Dec2024.pdf>.

Management will host a virtual investor presentation tomorrow Tuesday, 04 March 2025 at 10:00 SAST. The webcast will be accessible at <https://www.acannual2024.co.za>.

This short-form announcement does not contain full or complete details and any investment decision by investors and/or shareholders should be based on consideration of the information contained in the summarised results for the six months ended 31 December 2024, copies of which are also available for inspection at the Company's offices on workdays during business hours (at no charge) or on request from the company secretary by email: lebohang.mpumlwana@afrocentrichealth.com

On behalf of the Board

Dr ATM Mokgokong
Chairman

Mr GN van Wyk
Group Chief Executive Officer

Johannesburg
3 March 2025

JSE Sponsor to AfroCentric



Questco Corporate Advisory Proprietary Limited